XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements - Assets/Liabilities Measured at Fair Value (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Cash and cash equivalents $ 22,675 $ 51,184
Quoted Price in Active Markets for Identical Instruments Level 1    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Cash and cash equivalents 1,618 1,314
Significant Other Observable Inputs Level 2    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Cash and cash equivalents 21,057 49,870
Processa Pharmaceuticals, Inc    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Processa common shares 1 4
Processa Pharmaceuticals, Inc | Quoted Price in Active Markets for Identical Instruments Level 1    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Processa common shares $ 1 $ 4
License agreement | Processa Pharmaceuticals, Inc    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Shares to be issued under agreement 51